Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
602
1 219.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vijaya Diagnostic Centre Ltd
Vijaya Diagnostic Centre Ltd
Interest Income Expense
Vijaya Diagnostic Centre Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Interest Income Expense
-₹239.9m
|
CAGR 3-Years
-102%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Interest Income Expense
-₹85.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-10%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Interest Income Expense
₹13.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Interest Income Expense
-₹255.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Interest Income Expense
₹26.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Interest Income Expense
-₹212.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Vijaya Diagnostic Centre Ltd
Glance View
Vijaya Diagnostic Centre Ltd. engages in the provision of diagnostic services. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-09-14. The firm is engaged in the business of providing a range of diagnostic services spanning pathological investigations, basic and high-end radiology, nuclear medicine and related healthcare services. The firm operates through the Diagnostic Services segment. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests, including computerized tomography (CT) scans, magnetic resonance imaging (MRI) scans, single photon emission computed tomography (SPECT) and advanced positron emission tomography CT (PET CT). The firm also offers a range of health and wellness packages to its customers as per their requirements. The firm has a diagnostic network with over 90 centers spread across 15 cities.
See Also
What is Vijaya Diagnostic Centre Ltd's Interest Income Expense?
Interest Income Expense
-239.9m
INR
Based on the financial report for Mar 31, 2024, Vijaya Diagnostic Centre Ltd's Interest Income Expense amounts to -239.9m INR.
What is Vijaya Diagnostic Centre Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-47%
Over the last year, the Interest Income Expense growth was -306%. The average annual Interest Income Expense growth rates for Vijaya Diagnostic Centre Ltd have been -102% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
